OS9 Antibodies
We offer OS9 Antibodies for use in common research applications: Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Simple Western, Western Blot. Each OS9 Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our OS9 Antibodies can be used in a variety of model species: Human, Mouse, Rat. Use the list below to choose the OS9 Antibody which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our OS9 polyclonal antibodies.
Alternate Names for OS9 Antibodies
anti-OS9 antibody, anti-Amplified in osteosarcoma 9 antibody, anti-endoplasmic reticulum lectin 2 antibody, anti-ERLEC2 antibody, anti-erlectin 2 antibody, anti-OS-9 antibody, anti-osteosarcoma amplified 9, endoplasmic reticulum associated protein antibody, anti-osteosarcoma amplified 9, endoplasmic reticulum lectin antibody, anti-protein OS-9 antibody
7 Results for "os9" in Primary Antibodies
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0004.jpg "Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: OS9 Antibody [BC100-520] - OS9 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/OS9-Antibody-Immunocytochemistry-Immunofluorescence-BC100-520-img0002.jpg)
![Western Blot: OS9 Antibody [BC100-520] - WB analysis of OS9 in 1. A431 cell lysate, 2. HepG2 cell lysate, 3. MCF7 cell lysate and 4. 3T3 cell lysate.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0001.jpg)
![Simple Western: OS9 Antibody [BC100-520] - Simple Western lane view shows a specific band for OS9 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/OS9-Antibody-Simple-Western-BC100-520-img0003.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482216.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483621.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482293.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Cellular localization of OS-9 & PHD2.(A) A lectin gel-shift assay was conducted to test for glycosylated proteins. Total cell lysates of U2OS cells were incubated in the presence or absence of the endoglycosidases EndoH & PNGaseF for 6 h at 37°C. Digest products were separated on a reducing 10% SDS-PAGE gel which contained concanavalin A co-polymerized in the top layer of the separating gel to retard mobility of glycosylated proteins [56]. Glycosylated OS-9 is indicated as ‘g’, deglycosylated OS-9 as ‘d’. (B) Detection of OS-9 & PHD2 in the nuclear fraction. HEK293 cells with & without transfection of the plasmid pcDNA3-OS-9 were separated into nuclear fraction (N) & postnuclear supernatant (PS), the latter containing cytoplasm & organelles. Western blot analysis included BiP, GAPDH & lamin A as typical marker proteins for the ER, the cytoplasm & the nucleus, respectively. (C) Detection of OS-9 & PHD2 in the cytoplasm. HEK293 cells were co-transfected with pcDNA3-OS-9 & pPHD2-V5. For hypoxia, cells were exposed to 3% O2 for 4 h. Cells were treated with 50 µg/ml digitonin & centrifuged to obtain a cytoplasmic (C) & an organelle fraction (O) & subjected to immunoblotting. (D) Isolation of cellular endomembranes. HEK293 cells were lysed mechanically by several passages through a 30½G needle. The postnuclear supernatant was processed further by ultra-centrifugation to separate the organelles (O) from the cytosol (C). High salt treatment (1 M KCl) of the organelle fraction produced a wash fraction (W) that contained dissociated peripheral membrane proteins. For immunoblot analysis of subcellular fractionations, cell aliquots were normalized for cell number prior to loading (B–D). Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483637.jpg)
![Western Blot: OS9 Antibody [BC100-520] - OS-9 shows no effect on regulation of HIF-1 alpha .Total cell lysates were used for SDS-PAGE & subsequent Western blotting. To generate nearly anoxic conditions, cells were exposed to an oxygen consuming chemical system or to 1% or 3% O2 for 4 h to generate hypoxia. (A) U2OS, HeLa & Hep3B cells were transiently transfected with the plasmid pOS-9-V5 48 h prior to the experiment. Lamin A & actin were used as loading controls. (B) U2OS cells were subjected to ER stress by incubation either with tunicamycin (1 µg/ml) or thapsigargin (0.5 µg/ml) for 20 h. To detect HIF-1 alpha under normoxia, cells were treated with DMOG (1 mM) for 4 h. A sample of DMSO-only treated cells was loaded to exclude unspecific side effects of the solvent. (C) U2OS cells were transduced with lentiviral construct pLKO.1-shRNA-OS-9 (shOS-9) mediating a stable knockdown of OS-9 expression. Control cells (c) were transduced with plasmid pLKO.1-puro. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482250.jpg)
![Knockdown Validated: OS9 Antibody [NB100-519] - Contribution and interaction of OS-9 for degradation of SHH proteins. Cells stably expressing the N278A-HA precursor were depleted of OS-9 by siRNA, and the fate of N278A was followed after cycloheximide (CHX) addition. All samples were analyzed by SDS-PAGE and immunoblotting with HA antibodies. Controls were treated with a commercial negative control siRNA. The samples were also immunoblotted for OS-9 to show the extent of depletion. Immunoblotting with GAPDH antibodies served as loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092164) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OS9-Antibody-Knockdown-Validated-NB100-519-img0010.jpg "<b>Genetic Strategies Validation. </b>Knockdown Validated: OS9 Antibody [NB100-519] - Contribution and interaction of OS-9 for degradation of SHH proteins. Cells stably expressing the N278A-HA precursor were depleted of OS-9 by siRNA, and the fate of N278A was followed after cycloheximide (CHX) addition. All samples were analyzed by SDS-PAGE and immunoblotting with HA antibodies. Controls were treated with a commercial negative control siRNA. The samples were also immunoblotted for OS-9 to show the extent of depletion. Immunoblotting with GAPDH antibodies served as loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092164) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: OS9 Antibody [NB100-519] - Detection of OS-9.1 and OS-9.2 in total HEK293 cells, HEK293 cells expressing OS-9.1 or OS-9.2 by western analysis.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-NB100-519-img0005.jpg)
![Immunohistochemistry: OS9 Antibody [NB100-519] - Staining of OS9 in mouse smooth muscle.](http://images.novusbio.com/fullsize/OS9-Antibody-Immunohistochemistry-NB100-519-img0009.jpg)
![Immunoprecipitation: OS9 Antibody [NB100-519] - Immunoprecipitation of OS-9.1 and OS-9.2 in total HEK293 cells, HEK293 cells expressing OS-9.1 or OS-9.2.](http://images.novusbio.com/fullsize/OS9-Antibody-Immunoprecipitation-NB100-519-img0008.jpg)
![Immunohistochemistry: OS9 Antibody (26H3) [NBP3-26446] - Image of OS9 Antibody (26H3) diluted at 1:100 and staining in paraffin-embedded human pancreatic tissue performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.](http://images.novusbio.com/fullsize/nbp3-26446_rabbit-os9-mab-26h3-2722024857333.jpg "Immunohistochemistry: OS9 Antibody (26H3) [NBP3-26446] - Image of OS9 Antibody (26H3) diluted at 1:100 and staining in paraffin-embedded human pancreatic tissue performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.")
![Western Blot: OS9 Antibody (26H3) [NBP3-26446] - Positive Western Blot detected in: HL-60 whole cell lysate, Hela whole cell lysate, Mouse kidney tissue. All lanes: OS9 Antibody at 1: 2000 Secondary: Goat polyclonal to rabbit IgG at 1/50000 dilution. Predicted band size: 76, 70, 68, 74, 66, 64, 70, 61 kDa Observed band size: 72-95 kDa](http://images.novusbio.com/fullsize/nbp3-26446_rabbit-os9-mab-26h3-282202411472140.jpg)
![Western Blot: OS9 Antibody [NBP2-93962] - Analysis of extracts of various cell lines, using OS9 at 1:3000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 15s.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-NBP2-93962-img0001.jpg "Western Blot: OS9 Antibody [NBP2-93962] - Analysis of extracts of various cell lines, using OS9 at 1:3000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 15s.")
![Immunohistochemistry-Paraffin: OS9 Antibody [NBP1-84803] - Staining of human placenta shows cytoplasmic positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/OS9-Antibody-Immunohistochemistry-Paraffin-NBP1-84803-img0006.jpg "Immunohistochemistry-Paraffin: OS9 Antibody [NBP1-84803] - Staining of human placenta shows cytoplasmic positivity in trophoblastic cells.")
![Immunohistochemistry-Paraffin: OS9 Antibody [NBP2-97288] - Immunochemical staining of human OS9 in human pancreas with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/OS9-Antibody-Immunohistochemistry-Paraffin-NBP2-97288-img0002.jpg "Immunohistochemistry-Paraffin: OS9 Antibody [NBP2-97288] - Immunochemical staining of human OS9 in human pancreas with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.")
![Immunohistochemistry-Paraffin: OS9 Antibody [NBP2-97288] - Immunochemical staining of human OS9 in human placenta with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/OS9-Antibody-Immunohistochemistry-Paraffin-NBP2-97288-img0001.jpg)